Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RAPP · as of Mar 31, 2025
Ownership Breakdown
79
Institutional Holders
▲ 10 vs Q4
$382.32M
Total Inst. Value
▼ $266.57M vs Q4
36.50M
Shares Outstanding
freeFloat 47.84%
38.10M
13F Shares Held
▲ 1.53M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RAPP largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TRV GP V, LLC pharmaceutical preparations | 7.14M | 36.99% | 36.99% | $71.57B | May 9, 2025 | — held |
TRV GP VI, LLC pharmaceutical preparations | 969.2K | 5.02% | 5.02% | $9.72B | May 9, 2025 | — held |
FMR LLC pharmaceutical preparations | 5.49M | 1.56% | 1.56% | $55.03B | May 12, 2025 | — held |
LOGOS GLOBAL MANAGEMENT LP pharmaceutical preparations | 208.9K | 1.08% | 1.08% | $2.10B | May 15, 2025 | — held |
ARCH VENTURE MANAGEMENT, LLC pharmaceutical preparations | 3.73M | 1.06% | 1.06% | $37.55B | May 15, 2025 | — held |
CORMORANT ASSET MANAGEMENT, LP pharmaceutical preparations | 2.94M | 83.39% | 83.39% | $29.50B | May 15, 2025 | — held |
CAPITAL INTERNATIONAL INVESTORS pharmaceutical preparations | 2.60M | 73.80% | 73.80% | $26.10B | May 12, 2025 | — held |
JOHNSON & JOHNSON pharmaceutical preparations | 2.50M | 70.83% | 70.83% | $25.06B | May 7, 2025 | — held |
SOFINNOVA INVESTMENTS, INC. pharmaceutical preparations | 2.00M | 56.59% | 56.59% | $20.02B | May 15, 2025 | — held |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. pharmaceutical preparations | 1.55M | 44.01% | 44.01% | $15.57B | May 14, 2025 | ▼ 85.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
22
Increased
+1.41M shares11
New Positions
first time holders7
Decreased
−425.3K shares0
Sold Out
fully exitedNet shares change (top 50)
+980.0K
+1.41M / −425.3K
Net new holders
+26
11 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RAPP insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
10
Sell transactions
0.00
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Third Rock Ventures V, L.P. 10 percent owner | May 26, 2026 | Sale | 18,572 | $40.05 | $743.8K | 6.28M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | May 11, 2026 | Sale | 133,618 | $40.24 | $5.38M | 6.30M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | May 7, 2026 | Sale | 271,495 | $40.12 | $10.89M | 6.44M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | May 8, 2026 | Sale | 5,018 | $40.31 | $202.3K | 6.43M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | Apr 17, 2026 | Sale | 426,005 | $40.32 | $17.18M | 6.71M | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 17, 2026 | Sale | 20,225 | $39.99 | $808.8K | 246.4K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 10, 2026 | Sale | 500 | $34.98 | $17.5K | 286.0K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 13, 2026 | Sale | 9,165 | $34.97 | $320.5K | 276.9K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 14, 2026 | Sale | 10,200 | $35.08 | $357.8K | 266.7K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 8, 2026 | Sale | 360 | $34.90 | $12.6K | 286.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Rapport Therapeutics, Inc. Common Stock (RAPP) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 52.16%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Rapport Therapeutics, Inc. Common Stock is TRV GP V, LLC, holding approximately 7.14 million shares — equal to 36.99% of outstanding shares — as of March 31, 2025.
A total of 79 institutional investors currently hold RAPP stock, with a combined institutional value of approximately $382,320,433 as of the most recent 13F filing period.
Frequently asked questions
RAPP ownershipRapport Therapeutics, Inc. Common Stock (RAPP) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is TRV GP V, LLC with a 36.99% stake. Company insiders hold 52.16%. Data sourced from SEC Form 13F as of March 31, 2025.